Facile synthesis of imidazo[1,2-a]pyridines via tandem reaction

Article abstract of DOI:10.3987/COM-09-11856

An efficient method for the synthesis of 5,6,7-trisubstituted imidazo[1,2-a]pyridines was developed. The products were obtained in good yields under mild conditions.

Full text of DOI:10.3987/COM-09-11856

HETEROCYCLES, Vol. 81, No. 1, 2010
185
HETEROCYCLES, Vol. 81, No. 1, 2010, pp. 185 - 194. © The Japan Institute of Heterocyclic Chemistry
Received, 17th October, 2009, Accepted, 12th November, 2009, Published online, 12th November, 2009
DOI: 10.3987/COM-09-11856
FACILE SYNTHESIS OF IMIDAZO[1,2-a]PYRIDINES VIA TANDEM
REACTION
Jiong Jia,1,2 Yan-Qing Ge,2 Xu-Tang Tao,1*and Jian-Wu Wang2*
1
State Key Laboratory of Crystal Materials, Shandong University, Jinan,
250100, P. R. China. E-mail: txt@icm. sdu.edu.cn
2 School of Chemistry and Chemical Engineering, Shandong University, Jinan,
250100, P. R. China. E-mail: jwwang@sdu.edu.cn
Abstract – An efficient method for the synthesis of 5,6,7-trisubstituted
imidazo[1,2-a]pyridines was developed. The products were obtained in good
yields under mild conditions.
Compounds containing azaindole ring systems have attracted considerable attention because of their
promising biological activity and use as important building blocks in natural and synthetic bioactive
compounds due to their isosterism with indole.1 Among them, the imidazo[1,2-a]pyridines (IP) have been
extensively studied because of their wide range of pharmacological activities such as antiviral,
antibacterial, antifungal, antiulcer, and anti-inflammatory behavior.2 Drugs containing
imidazo[1,2-a]pyridines such as Alpidem, Zolpidem, Necopidem, Olprinone, Divalpon and Zolimidine
are currently available on the market.
Although a number of versatile imidazo[1,2-a]pyridines (IP) synthesis have been reported to create
heterocyclic compounds with potential therapeutic applications, the development of new methods for the
synthesis of IPs remains an active area of research.3 The classical approach involves the coupling of
2-aminopyridines with α-halocarbonyl compounds.4 Groebke-Blackburn multi-component reaction
involving the condensation of aldehydes, 2-aminopyridine, and isocyanides provides a more efficient and
versatile approach.5 This robust approach allows for the preparation of a diverse range of products.
Additionally, a number of other methods were reported to evaluate their chemical and pharmacological
properties.6 However, direct introduction of a number of substituents into the pyridine moiety of the
imidazo[1,2-a]pyridine core in synthesis was poorly studied.7
We recently reported a direct synthesis of indolizines and pyrazolo[1,5-a]pyridines via a new tandem
reaction.8 Our method proceeds under very mild conditions at room temperature in good yields (65-85%).

186
HETEROCYCLES, Vol. 81, No. 1, 2010
In continuation of our work on nitrogen-bridged heterocycles, we wish to expand this strategy as an
convenient synthetic method for the synthesis of 5,6,7-trisubstituted imidazo[1,2-a]pyridines.
Imidazo[1,2-a]pyridines 3a-b were synthesized through the reaction of the commercially available
imidazole-2-carbaldehyde 1 and α,β-unsaturated esters 2a-b in the presence of K2CO3 at room
temperature in 81% and 73% yield by the established procedure (Scheme 1).8
This method afforded an easy and efficient way to prepare imidazo[1,2-a]pyridines which prompted us to
extend the tandem reaction to the preparation of 5,6,7-trisubstituted imidazo[1,2-a]pyridines. A set of
substituted 2-benzoyl imidazoles 6a-g were readily prepared by treatment of lithium salt of imidazole 4
with 1.1 equiv of substituded phenylaldehydes, followed by oxidation of the resulting
hydroxybenzylimidazoles 5a-g (Scheme 2).9
H
R1
CO2Et
R1
N
N
K2CO3
DMF
Br
CO2Et
CHO
N
N
3a R1 = H
3b R1 = Me
1
2a-b
Scheme 1
OH
R2
N
O
N
R2
R3
N
N
1. n-BuLi
2. aldehyde
CrO3
HOAc
N
Tr
N
H
Tr
R4
5a-g
R3
R4
6a-g
4
Scheme 2
In view of the high efficiency of K2CO3/DMF system on the synthesis of imidazo[1,2-a]pyridines, we
chose it as a base to perform this one-pot reaction of poly substituted imidazo[1,2-a]pyridines and the
results were given in Table 1. The desired imidazo[1,2-a]pyridines 3c-p were obtained by the reaction of
substituted 2-benzoylimidazoles 6a-g and α,β-unsaturated esters 2a-b in the presence of K2CO3 in dry
DMF at room temperature for 2-6 h. A wide range of substituted 2-benzoylimidazoles 6 reacted
effectively with α,β-unsaturated esters 2a-b including a variety of electron-donating and
electron-withdrawing substituents.
The structures of products 3a-p were characterized by spectroscopic methods (1H and 13C NMR, IR, and
HRMS). The structure of 3a was further confirmed by X-ray crystallographic analysis as shown in Figure
1.
We believe that this reaction proceed by an intermolecular SN2 reaction, deprotonation, and then electron
pair transfer, cyclization, followed by elimination, to form the desired final products.8
In summary, we have developed an efficient synthetic approach to 5,6,7-trisubstituted
imidazo[1,2-a]pyridines by a tandem reaction involving an intermolecular SN2 reaction, deprotonation,

HETEROCYCLES, Vol. 81, No. 1, 2010
187
Figure 1. Crystal structure of 3a
Table 1. Reaction of Imidazole with Unsaturated Esters to Generate Imidazo[1,2-a]pyridines
R
R1
R
O
CO2Et
R1
N
N
K2CO3
DMF
CO2Et
+
N
N
H
Br
3c-p
6a-g
2a-b
Entry
1
R
R1
H
Me
H
Me
H
Me
H
Me
H
Me
H
Me
H
Me
Product
3c
Isolated Yield(%)
4-MeC6H4
4-MeC6H4
4-MeOC6H4
4-MeOC6H4
80
75
75
61
72
63
80
72
86
80
88
81
83
76
2
3
4
5
6
7
8
9
10
11
12
13
14
3d
3e
3f
3g
3h
3i
3j
3k
3l
3m
3n
3o
1,3-benzodioxol-5-yl
1,3-benzodioxol-5-yl
Ph
Ph
4-NO2C6H4
4-NO2C6H4
4-NO2C6H4
4-NO2C6H4
2,4-Cl2C6H4
2,4-Cl2C6H4
3p
electron pair transfer, cyclization and elimination. These reactions proceeded under very mild conditions
and a wide range of title compounds were synthesized. A study of the fluorescence properties and
potential biological activity of these compounds will be presented in due course.
EXPERIMENTAL
All reagents and solvents were purchased from Sinopharm Chemical Reagent Co. Ltd and used without
further purification unless otherwise noted. Starting materials were prepared according to literatures.
1
Thin-layer chromatography (TLC) was conducted on silica gel 60 F254 plates (Merck KGaA). H NMR
spectra were recorded on a Bruker Avance 300 (300 MHz) spectrometer, using CDCl3 or DMSO-d6 as
solvents and tetramethylsilane (TMS) as an internal standard. Melting points were determined on an
XD-4 digital micro-melting point apparatus and are uncorrected. IR spectra were recorded with an IR

188
HETEROCYCLES, Vol. 81, No. 1, 2010
spectrophotometer Avtar 370 FT-IR (Termo Nicolet). Elemental analyses were performed on a Vario EL
III (Elementar Analysensysteme GmbH) spectroanalyzer. MS spectra were recorded on a LTQ Orbitrap
Hybrid mass spectrograph.
General procedure for the synthesis and analytical data of 6a-g
1-Trityl-lithioimidazole was prepared by the addition of 4.8 mL of 2.5 M n-butyllithium in hexane to a
solution of 3.10 g (10 mmol) of 1-tritylimidazole 4 in 60 mL of tetrahydrofuran (freshly distilled from
lithium aluminum hydride) at 0 °C under a nitrogen atmosphere. The solution, which gradually turned red,
was stirred at room temperature for 1.5 h, was then cooled to 0 °C, and 12 mmol of aldehydes were added.
After an additional 30 min at room temperature, the reaction mixture was poured into 200 mL of water
and then filtered. The precipitate was collected and the crude products 5 were used in the following step
without further purification.
A solution of chromium trioxide (0.60 g, 6.0 mmol) in water (2 mL) was added dropwise to a solution of
hydroxybenzylimidazoles 5 (8.0 mmol) in glacial acid (20 mL) at 90 °C. The reaction mixture was heated
at 100 °C for a further 5 min, and then poured into 100 mL of water and filtered. The filtrate was
extracted with CH2Cl2 (3 x 30 mL). The combined extracts were washed with brine (2 x 20 mL), dried
over MgSO4 and filtered, and the solvent was removed by rotary evaporation. The crude products 6 were
purified by recrystallization from EtOAc.
(1H-Imidazol-2-yl)(phenyl)methanone 6a10
1H NMR (300 MHz, CDCl3): δ 11.12 (s, 1H), 8.58 (d, 2H, J = 7.8 Hz), 7.50-7.64 (m, 3H), 7.41 (s, 1H),
7.28 (s, 1H). 13C NMR (75 MHz, CDCl3): δ 182.2, 145.3, 135.6, 133.4, 131.9, 131.0, 128.4, 120.3.
(1H-Imidazol-2-yl)(p-tolyl)methanone 6b10
1H NMR (300 MHz, CDCl3): δ 10.86 (s, 1H), 8.52 (d, 2H, J = 8.4 Hz), 7.39 (s, 1H), 7.32 (d, 2H, J = 8.4
13
Hz), 7.28 (s, 1H), 2.44 (s, 3H). C NMR (75 MHz, CDCl3): δ 181.5, 145.5, 144.4, 133.0, 131.7, 131.2,
129.1, 119.8, 21.8.
(1H-Imidazol-2-yl)(4-methoxyphenyl)methanone 6c10
1H NMR (300 MHz, CDCl3): δ 10.92 (s, 1H), 8.69 (d, 2H, J = 9.0 Hz), 7.38 (s, 1H), 7.27 (s, 1H), 7.00 (d,
13
2H, J = 9.0 Hz), 3.90 (s, 3H). C NMR (75 MHz, CDCl3): δ 180.3, 164.1, 145.6, 133.6, 131.6, 128.5,
119.6, 113.7, 55.5.
Benzo[d][1,3]dioxol-5-yl(1H-imidazol-2-yl)methanone 6d
1H NMR (300 MHz, CDCl3): δ 10.87 (s, 1H), 8.50 (dd, 1H, J = 1.5, 8.4 Hz), 8.07 (d, 1H, J = 1.8 Hz),
13
7.30 (d, 3H, J = 8.4 Hz), 6.94 (d, 1H, J = 8.4 Hz), 6.06 (s, 2H). C NMR (75 MHz, CDCl3): δ 179.7,
152.3, 147.9, 145.4, 130.0, 128.4, 127.9, 127.3, 110.5, 108.0, 101.8. HRMS: m/z calcd for C11H9N2O3
[M+H]+ 217.0613, found 217.0616.

HETEROCYCLES, Vol. 81, No. 1, 2010
189
(2,4-Dichlorophenyl)(1H-imidazol-2-yl)methanone 6e
1H NMR (300 MHz, CDCl3): δ 10.76 (s, 1H), 7.81 (d, 1H, J = 8.4 Hz), 7.51 (d, 1H, J = 1.8 Hz), 7.36-7.39
13
(m, 3H). C NMR (75 MHz, CDCl3): δ 182.2, 144.7, 137.8, 134.1, 133.6,132.1, 130.5, 126.8. HRMS:
m/z calcd for C10H7Cl2N2O [M+H]+ 240.9935, found 240.9934.
(1H-Imidazol-2-yl)(3-nitrophenyl)methanone 6f11
1H NMR (300 MHz, DMSO-d6): δ 13.69 (s, 1H), 9.40 (t, 1H, J = 1.8 Hz), 8.82-8.86 (m, 1H), 8.49-8.53
(m, 1H), 7.88 (t, 1H, J = 7.8 Hz), 7.62 (s, 1H), 7.39 (s, 1H). 13C NMR (75 MHz, CDCl3): δ 178.9, 148.1,
144.8, 137.5, 136.9, 132.1, 130.5, 127.7, 125.9, 123.3.
(1H-Imidazol-2-yl)(4-nitrophenyl)methanone 6g10
1H NMR (300 MHz, DMSO-d6): δ 13.69 (s, 1H), 8.65 (d, 2H, J = 9.0 Hz), 8.38 (d, 2H, J = 9.0 Hz), 7.62
(d, 1H, J = 1.8 Hz), 7.37 (s, 1H). 13C NMR (75 MHz, CDCl3): δ 178.9, 148.1, 144.8, 137.5, 136.9, 132.1,
130.5, 127.7, 125.9, 123.3.
General procedure for the synthesis and analytical data of 3a-3p
To a 50-mL round-bottomed flask were added 1 or 6 (1.00 mmol), enoate 2 (1.20 mmol), potassium
carbonate (0.283 g, 2.05 mmol) and dry DMF (10 mL). The mixture was stirred at rt for 3 h and then
filtered. The filtrate was poured into water (100 mL) and extracted with CH2Cl2 (3 x 30 mL). The
combined extracts were washed with water, dried over anhydrous MgSO4 and filtered, and the solvent
was removed by rotary evaporation. The crude products were purified by column chromatography.
Ethyl imidazo[1,2-a]pyridine-7-carboxylate (3a)
1
White solid (81% yield): mp 294-297 °C. H NMR (300 MHz, CDCl3): δ 8.38 (s, 1H), 8.17 (d, 1H, J =
6.9 Hz), 7.80 (s, 1H), 7.70 (s, 1H), 7.41 (dd, 1H, J = 1.2, 6.9 Hz), 4.38-4.46 (q, 2H, J = 7.2 Hz), 1.40-1.45
(t, 3H, J = 7.2 Hz). 13C NMR (75.4 MHz, CDCl3): δ 165.2, 136.0, 126.3, 125.3, 120.6, 113.8, 111.7, 61.5,
14.3. IR (KBr) ν = 3393, 2980, 1710, 1500, 1369, 1321, 1245, 1021, 761 cm−1. HRMS: m/z calcd for
C10H11N2O2 [M+H]+ 191.0821, found 191.0823. Anal. Calcd for C10H10N2O2: C, 63.15; H, 5.30; N, 14.73.
Found: C, 63.16; H, 5.31; N, 14.73.
Ethyl 6-methylimidazo[1,2-a]pyridine-7-carboxylate (3b)
White solid (73% yield): mp 146-148 °C. 1H NMR (300 MHz, CDCl3): δ 8.32 (s, 1H), 7.96 (s, 1H), 7.74
(s, 1H), 7.59 (s, 1H), 4.35-4.42 (q, 2H, J = 7.2 Hz), 2.54 (s, 3H), 1.40-1.45 (t, 3H, J = 7.2 Hz). 13C NMR
(75.4 MHz, CDCl3): δ 165.9, 135.7, 127.1, 124.6, 121.9, 121.1,112.9, 61.2, 18.5, 14.3. IR (KBr) ν = 2976,
1692, 1508, 1438, 1328, 1261, 1059, 734 cm−1. HRMS: m/z calcd for C11H13N2O2 [M+H]+ 205.0977,
found 205.0977. Anal. Calcd for C11H12N2O2: C, 64.69; H, 5.92; N, 13.72. Found: C, 64.67; H, 5.92; N,
13.74.
Ethyl 8-p-tolylimidazo[1,2-a]pyridine-7-carboxylate (3c)
White solid (80% yield): mp 107-110 °C. 1H NMR (300 MHz, CDCl3): δ 8.14 (d, 1H, J = 7.2 Hz), 7.73 (s,

190
HETEROCYCLES, Vol. 81, No. 1, 2010
1H), 7.68 (d, 1H, J = 1.2 Hz), 7.35 (d, 2H, J = 8.1 Hz), 7.25-7.29 (m, 3H), 4.07-4.14 (q, 2H, J = 7.2 Hz),
13
2.41 (s, 3H), 0.99-1.04 (t, 3H, J = 7.2 Hz). C NMR (75.4 MHz, CDCl3): δ 167.0, 144.6, 135.7, 135.6,
133.1, 129.2, 128.1, 125.2, 124.4, 113.9, 112.7, 61.2, 13.5. IR (KBr) ν = 3152, 2981, 1711, 1490, 1332,
1255, 1018, 784 cm−1. HRMS: m/z calcd for C17H17N2O2 [M+H]+ 281.1290, Found 281.1293. Anal. Calcd
for C17H16N2O2: C, 72.84; H, 5.75; N, 9.99. Found: C, 72.88; H, 5.75; N, 9.98.
Ethyl 6-methyl-8-p-tolylimidazo[1,2-a]pyridine-7-carboxylate (3d)
White solid (75% yield): mp 86-89 °C. 1H NMR (300 MHz, CDCl3): δ 7.94 (d, 1H, J = 0.9 Hz), 7.72 (d, 1
H, J = 0.9 Hz), 7.67 (d, 1H, J = 0.9 Hz), 7.45 (d, 2H, J = 8.1 Hz), 7.25 (d, 2H, J = 8.1 Hz), 4.06-4.16 (q,
2H, J = 7.2 Hz), 2.38 (s, 3H), 2.33 (d, 3H, J = 0.9 Hz), 0.97-1.02 (t, 3H, J = 7.2 Hz). 13C NMR (75.4 MHz,
CDCl3): δ 167.9, 143.5, 138.2, 134.7, 131.9, 130.0, 129.3, 129.1, 129.0, 128.8, 123.1, 119.3, 112.8, 112.7,
61.3, 21.3, 16.7, 13.7. IR (KBr) ν = 2980, 1722, 1492, 1333, 1260, 1068, 718 cm−1. HRMS: m/z calcd for
C18H19N2O2 [M+H]+ 295.1447, found: 295.1448. Anal. Calcd for C18H18N2O2: C, 73.45; H, 6.16; N, 9.52.
Found: C,73.48; H, 6.17; N, 9.47.
Ethyl 8-(4-methoxyphenyl)imidazo[1,2-a]pyridine-7-carboxylate (3e)
Yellow oil (75% yield). 1H NMR (300 MHz, CDCl3): δ 8.13 (d, 1H, J = 7.2 Hz), 7.73 (d, 1H, J = 1.2 Hz),
7.68 (d, 1H, J = 1.2 Hz), 7.40-7.45 (m, 2H), 7.26 (d, 1H, J = 6.9 Hz), 6.98-7.03 (m, 2H), 4.09-4.16 (q, 2H,
13
J = 7.2 Hz), 3.85 (s, 3H), 1.02-1.07 (t, 3H, J = 7.2 Hz). C NMR (75.4 MHz, CDCl3): δ 167.2, 159.7,
144.9, 135.7, 132.9, 130.6, 127.7, 125.0, 124.0, 113.8, 113.6, 112.8, 61.2, 55.3, 13.8. IR (KBr) ν = 2958,
1710, 1487, 1231, 1140, 1030, 825, 749 cm−1. HRMS: m/z calcd for C17H17N2O3 [M+H]+ 297.1239, found
297.1242. Anal. Calcd for C17H16N2O3: C, 68.91; H, 5.44; N, 9.45. Found: C, 68.95; H, 5.45; N, 9.46.
Ethyl 8-(4-methoxyphenyl)-6-methylimidazo[1,2-a]pyridine-7-carboxylate (3f)
1
Yellow oil (61% yield). H NMR (300 MHz, CDCl3): δ 7.96 (d, 1H, J = 0.9 Hz), 7.63 (s, 1H), 7.58 (s,
1H), 7.50 (d, 2H, J = 7.2 Hz), 6.98 (d, 2H, J = 7.2 Hz), 7.00 (dd, 1H, J = 1.8, 8.1 Hz), 6.88 (d, 1H, J = 8.1
Hz), 5.99 (s, 2H), 4.08-4.15 (q, 2H, J = 7.2 Hz), 3.83 (s, 3H), 2.32 (d, 3H, J = 0.9 Hz), 1.00-1.05 (t, 3H, J
= 7.2 Hz). 13C NMR (75.4 MHz, CDCl3): δ 167.9, 159.8, 143.4, 134.4, 130.9, 130.7, 130.2, 128.6, 127.0,
123.1, 119.4, 113.8, 113.0, 61.3, 55.3, 16.7, 13.8. IR (KBr) ν = 2928, 1721, 1609, 1501, 1249, 1031, 832,
727 cm−1. HRMS: m/z calcd for C18H19N2O3 [M+H]+ 311.1396, found 311.1396. Anal. Calcd for
C18H18N2O3: C, 69.66; H, 5.85; N, 9.03. Found: C, 69.69; H, 5.85; N, 9.03.
Ethyl 8-(benzo[d][1,3]dioxol-5-yl)imidazo[1,2-a]pyridine-7-carboxylate (3g)
White solid (72% yield): mp 147-150 °C. 1H NMR (300 MHz, CDCl3): δ 8.16 (d, 1H, J = 6.9 Hz), 7.72 (d,
2H, J = 9.9 Hz), 7.26 (d, 1H, J = 6.9 Hz), 6.99 (s, 1H), 6.89 (s, 2H), 5.99 (s, 2H), 4.12-4.19 (q, 2H, J =
7.2 Hz), 1.07-1.12 (t, 3H, J = 7.2 Hz). 13C NMR (75.4 MHz, CDCl3): δ 166.9, 147.7, 147.4, 144.6, 135.5,
132.5, 131.0, 128.9, 124.3, 123.0, 113.9, 112.8, 110.1, 108.2, 101.2, 61.3, 13.8. IR (KBr) ν = 2981, 1723,
1477, 1220, 1141, 1034, 781 cm−1. HRMS: m/z calcd for C17H15N2O4 [M+H]+ 311.1032, found 311.1033.

HETEROCYCLES, Vol. 81, No. 1, 2010
191
Anal. Calcd for C17H14N2O4: C, 65.80; H, 4.55; N, 9.03. Found: C, 65.85; H, 4.56; N, 9.03.
Ethyl 8-(benzo[d][1,3]dioxol-5-yl)-6-methylimidazo[1,2-a]pyridine-7-carboxylate (3h)
Yellow oil (63% yield). 1H NMR (300 MHz, CDCl3): δ 7.95 (d, 1H, J = 0.9 Hz), 7.64 (d, 1H, J = 1.2 Hz),
7.57 (d, 1H, J = 0.9 Hz), 7.10 (d, 1H, J = 1.8 Hz), 7.00 (dd, 1H, J = 1.8, 8.1 Hz), 6.88 (d, 1H, J = 8.1 Hz),
13
5.99 (s, 2H), 4.12-4.19 (q, 2H, J = 7.2 Hz), 2.33 (d, 3H, J = 0.9 Hz), 1.06-1.11 (t, 3H, J = 7.2 Hz). C
NMR (75.4 MHz, CDCl3): δ 167.8, 147.9, 147.6, 143.4, 134.7, 130.2, 128.6, 128.4, 123.2, 123.2, 119.3,
112.9, 110.2, 108.3, 101.2, 61.4, 16.7, 13.9. IR (KBr) ν = 2980, 1723, 1671, 1490, 1238, 1037, 811 cm−1.
HRMS: m/z calcd for C18H17N2O4 [M+H]+ 325.1188, found 325.1188. Anal. Calcd for C18H16N2O4: C,
66.66; H, 4.97; N, 8.64. Found: C, 66.68; H, 4.97; N, 8.64.
Ethyl 8-phenylimidazo[1,2-a]pyridine-7-carboxylate (3i)
Yellow oil (80% yield). 1H NMR (300 MHz, CDCl3): δ 8.13 (d, 1H, J = 7.2 Hz), 7.72 (s, 1H), 7.68 (d, 1H,
J = 0.6 Hz), 7.43-7.47 (m, 5H), 7.27 (d, 1H, J = 7.2 Hz), 4.04-4.11 (q, 2H, J = 7.2 Hz), 0.93-0.98 (t, 3H, J
= 7.2 Hz). 13C NMR (75.4 MHz, CDCl3): δ 167.0, 144.6, 135.7, 135.6, 133.1, 129.2, 128.1, 125.2, 124.4,
113.9, 112.7, 61.2, 13.5. IR (KBr) ν = 2982, 1711, 1487, 1334, 1267, 1150, 1023, 766, 702 cm−1. HRMS:
m/z calcd for C16H15N2O2 [M+H]+ 267.1134, found 267.1137. Anal. Calcd for C16H14N2O2: C, 72.16; H,
5.30; N, 10.52. Found: C, 72.19; H, 5.30; N, 10.53.
Ethyl 6-methyl-8-phenylimidazo[1,2-a]pyridine-7-carboxylate (3j)
1
White solid (72% yield): mp 105-108 °C. H NMR (300 MHz, CDCl3): δ 7.97 (s, 1H), 7.66 (s, 1H),
7.54-7.59 (m, 3H), 7.37-7.48 (m, 3H), 4.02-4.10 (q, 2H, J = 7.2 Hz), 2.35 (s, 3H), 0.93-0.97 (t, 3H, J =
13
7.2 Hz). C NMR (75.4 MHz, CDCl3): δ 167.8, 143.4, 134.9, 134.8, 130.1, 129.4, 129.3, 128.4, 128.3,
123.3, 119.3, 112.9, 61.3, 16.8, 13.6. IR (KBr) ν = 2983, 1720, 1491, 1256, 1181, 1064, 698 cm−1.
HRMS: m/z calcd for C17H17N2O2 [M+H]+ 281.1290, found 281.1291. Anal. Calcd for C17H16N2O2: C,
72.84; H, 5.75; N, 9.99. Found: C, 72.84; H, 5.76; N, 10.01.
Ethyl 8-(4-nitrophenyl)imidazo[1,2-a]pyridine-7-carboxylate (3k)
Yellow solid (86% yield): mp 138-139 °C. 1H NMR (300 MHz, CDCl3): δ 8.35-8.37 (m, 2H), 7.33 (d, 1H,
J = 4.5 Hz), 7.77 (s, 2H), 7.61-7.65 (m, 2H), 7.43 (d, 1H, J = 6.9 Hz), 4.11-4.18 (q, 2H, J = 7.2 Hz),
13
1.04-1.08 (t, 3H, J = 7.2 Hz). C NMR (75.4 MHz, CDCl3): δ 165.7, 147.6, 144.0, 142.7, 136.3, 131.3,
130.4, 125.2, 124.7, 123.3, 114.2, 112.8, 61.6, 13.7. IR (KBr) ν = 2990, 1729, 1513, 1344, 1240, 1154,
1028, 740 cm−1. HRMS: m/z calcd for C16H14N3O4 [M+H]+ 312.0984, found 312.0986. Anal. Calcd for
C16H13N3O4: C, 61.73; H, 4.21; N, 13.50. Found: C, 61.78; H, 4.22; N, 13.51.
Ethyl 6-methyl-8-(4-nitrophenyl)imidazo[1,2-a]pyridine-7-carboxylate (3l)
1
Yellow solid (80% yield): mp 132-134 °C. H NMR (300 MHz, CDCl3): δ 8.31-8.35 (m, 2H), 8.06 (s,
1H), 7.74-7.79 (m, 2H), 7.65-7.68 (m, 2H), 4.08-4.15 (q, 2H, J = 7.2 Hz), 2.38 (s, 3H), 1.00-1.05 (t, 3H, J
= 7.2 Hz). 13C NMR (75.4 MHz, CDCl3): δ 167.1, 147.7, 142.6, 141.8, 135.2, 130.7, 130.3, 126.8, 124.4,

192
HETEROCYCLES, Vol. 81, No. 1, 2010
123.4, 119.5, 113.3, 61.7, 16.8, 13.8. IR (KBr) ν = 2981, 1738, 1519, 1347, 1251, 1181, 1063, 847, 709
cm−1. HRMS: m/z calcd for C17H16N3O4 [M+H]+ 326.1141, found 326.1145. Anal. Calcd for C17H15N3O4:
C, 62.76; H, 4.65; N, 12.92. Found: C, 62.77; H, 4.66; N, 12.93.
Ethyl 8-(3-nitrophenyl)imidazo[1,2-a]pyridine-7-carboxylate (3m)
Yellow solid (88% yield): mp 146-147 °C. 1H NMR (300 MHz, CDCl3): δ 8.30-8.34 (m, 2H), 8.24 (d, 1H,
J = 7.2 Hz), 7.77-7.82 (m, 3H), 7.63-7.69 (m, 1H), 7.44 (d, 1H, J = 7.2 Hz), 4.10-4.17 (q, 2H, J = 7.2 Hz),
13
1.02-1.07 (t, 3H, J = 7.2 Hz). C NMR (75.4 MHz, CDCl3): δ 165.7, 148.1, 144.3, 137.3, 136.3, 135.6,
131.1, 128.9, 125.1, 124.9, 124.7, 123.1, 114.3, 112.9, 61.5, 13.7. IR (KBr) ν = 2991, 1718, 1531, 1346,
1231, 1153, 1030, 740 cm−1. HRMS: m/z calcd for C16H14N3O4 [M+H]+ 312.0984, found 312.0986. Anal.
Calcd for C16H13N3O4: C, 61.73; H, 4.21; N, 13.50. Found: C, 61.74; H, 4.21; N, 13.53.
Ethyl 6-methyl-8-(3-nitrophenyl)imidazo[1,2-a]pyridine-7-carboxylate (3n)
1
Yellow oil (81% yield). H NMR (300 MHz, CDCl3): δ 8.46 (s, 1H), 8.29 (d, 1H, J = 8.1 Hz), 8.06 (s,
1H), 7.94 (d, 1H, J = 7.5 Hz), 7.63-7.67 (m, 3H), 4.10-4.17 (q, 2H, J = 7.2 Hz), 2.38 (s, 3H), 1.03-1.08 (t,
3H, J = 7.2 Hz). 13C NMR (75.4 MHz, CDCl3): δ 167.1, 148.1, 142.7, 136.6, 135.8, 135.1, 129.3, 126.4,
124.7, 124.4, 123.3, 119.4, 113.4, 61.6, 16.8, 13.8. IR (KBr) ν = 2977, 1719, 1533, 1347, 1251, 1068, 748
cm−1. HRMS: m/z calcd for C17H16N3O4 [M+H]+ 326.1141, found 326.1145. Anal. Calcd for C17H15N3O4:
C, 62.76; H, 4.65; N, 12.92. Found: C, 62.78; H, 4.66; N, 12.93.
Ethyl 8-(2,4-dichlorophenyl)imidazo[1,2-a]pyridine-7-carboxylate (3o)
Yellow oil (83% yield). 1H NMR (300 MHz, CDCl3): δ 8.22 (d, 1H, J = 7.2 Hz), 7.75 (d, 1H, J = 0.9 Hz),
7.73 (d, 1H, J = 0.9 Hz), 7.53 (d, 1H, J = 2.1 Hz), 7.48(d, 1H, J = 7.2 Hz), 7.37 (dd, 1H, J = 2.1, 8.1 Hz),
7.29 (d, 1H, J = 8.1 Hz), 4.14-4.18 (q, 2H, J = 7.2 Hz), 1.05-1.10 (t, 3H, J = 7.2 Hz). 13C NMR
(75.4 MHz, CDCl3): δ 165.3, 144.1, 136.2, 134.7, 134.0, 133.7, 131.3, 129.9, 129.2, 126.9, 125.1, 125.0,
114.1. 112.7. 61.4. 13.6. IR (KBr) ν = 2982, 1717, 1589, 1492, 1372, 1333, 1023, 749 cm−1. HRMS: m/z
calcd for C16H13Cl2N2O2 [M+H]+ 335.0354, found 335.0357. Anal. Calcd for C16H12Cl2N2O2: C, 57.33; H,
3.61; N, 8.36. Found: C, 57.36; H, 3.60; N, 8.36.
Ethyl 8-(2,4-dichlorophenyl)-6-methylimidazo[1,2-a]pyridine-7-carboxylate (3p)
White solid (76% yield): mp 152-154 °C. 1H NMR (300 MHz, CDCl3): δ 8.03 (d, 1H, J = 1.2 Hz), 7.66 (d,
1H, J = 1.2 Hz), 7.60 (d, 1H, J = 1.2 Hz), 7.53 (d, 1H, J = 1.8 Hz), 7.26-7.35 (m, 2H), 4.05-4.13 (q, 2H, J
= 7.2 Hz), 2.40 (d, 3H, J = 0.9 Hz), 0.98-1.03 (t, 3H, J = 7.2 Hz). 13C NMR (75.4 MHz, CDCl3): δ 166.5,
142.7, 135.2, 135.1, 134.9, 132.9, 131.9, 130.3, 129.5, 126.9, 126.5, 124.4, 119.6, 113.0, 61.3, 17.1, 13.6.
IR (KBr) ν = 2958, 1732, 1497, 1336, 1182, 1050, 731 cm−1. HRMS: m/z calcd for C17H14Cl2N2O2
[M+H]+ 349.0511, found 349.0511. Anal. Calcd for C17H15Cl2N2O2: C, 58.47; H, 4.04; N, 8.02. Found: C,
58.49; H, 6.45; N, 8.03.

HETEROCYCLES, Vol. 81, No. 1, 2010
193
ACKNOWLEDGEMENTS
The authors thank the Shandong Natural Science Foundation (No. Y2008B40) and Shandong Excellent
Young and Mid-aged Scientist Promotive Foundation (No. 2008BS04024) for financial support of this
work.
REFERENCES
1. J. M. Chezal, E. Moreau, G. Delmas, A. Gueiffier, Y. Blache, G. Grassy, C. Lartigue, O. Chavignon,
and J. C. Teulade, J. Org. Chem., 2001, 66, 6576 and references therein; K. Panda, J. R. Suresh, H.
Ila, and H. Junjappa, J. Org. Chem., 2003, 68, 3498; S. V. Ryabukhin, A. S. Plaskon, D. M.
Volochnyuk, and A. A. Tolmachev, Synthesis, 2007, 20, 3155; G. Toth, A. Kovacs, M. Balogh, and I.
Hermecz, J. Heterocycl. Chem., 1991, 28, 497.
2. A. Gueiffier, M. Lhassani, A. Elhakmaoui, R. Snoeck, G. Andrei, O. Chavignon, J. C. Teulade, A.
Kerbal, E. M. Essassi, J. C. Debouzy, M. Witvrouw, Y. Blache, J. Balzarini, E. De Clercq, and J. P.
Chapat, J. Med. Chem., 1996, 39, 2856; J. B. Véron, H. Allouchi, C. Enguehard-Gueiffier, R.
Snoeck, G. Andrei, E. De Clercq, and A. Gueiffier, Bioorg. Med. Chem., 2008, 16, 9536; K. S.
Gudmundsson, J. D. Williams, J. C. Drach, and L. B. Townsend, J. Med. Chem., 2003, 46, 1449; M.
Lhassani, O. Chavignon, J. M. Chezal, J. C. Teluade, J. P. Chapat, R. Snoeck, G. Andrei, J. Balzarini,
E. De Clercq, and A. Gueiffier, Eur. J. Med. Chem., 1999, 34, 271; Y. Rival, G. Grassy, and G.
Michael, Chem. Pharm. Bull., 1992, 40, 1170; J. J. Kaminsky and A. M. Doweyko, J. Med. Chem.,
1999, 40, 427; K. C. Rupert, J. R. Henry, J. H. Dodd, S. A. Wadsworth, D. E. Cavender, G. C. Olini,
B. Fahmy, and J. J. Siekierka, Bioorg. Med. Chem. Lett., 2003, 13, 347.
3. M. Adib, M. Mahdavi, A. Abbasi, A. H. Jahromia, and H. R. Bijanzadehb, Tetrahedron Lett., 2007,
48, 3217 and references therein; A. R. Katritzky, Y. J. Xu, and H. Tu, J. Org. Chem., 2003, 68, 4935
and references therein.
4. H. J. Knölker, R. Boese, and R. Hitzemann, Chem. Ber., 1990, 123, 327.
5. K. Groebke, L. Weber, and F. Mehlin, Synlett, 1998, 661; C. Blackburn, B. Guan, P. Fleming, K.
Shiosaki, and S. Tsai, Tetrahedron Lett., 1998, 39, 3635; H. Bienaymé and K. Bouzid, Angew. Chem.
Int. Ed., 1998, 37, 2234.
6. E. F. DiMauro and J. M. Kennedy, J. Org. Chem., 2007, 72, 1013; I. Veljkovic, R. Zimmer, H. U.
Reissig, I. Brüdgam, and H. Hartl, Synthesis, 2006, 19, 2677; A. K. Nadipuram and S. M. Kerwin,
Tetrahedron, 2006, 62, 3798; C. Hamdouchi, J. De-Blas, and J. Ezquerra, Tetrahedron, 1999, 55,
541; M. Adib, E. Sheibani, H. R. Bijanzadeh, and L. G. Zhu, Tetrahedron, 2008, 64, 10681; J. S.
Yadav, B. V. Subba Reddy, Y. G. Rao, M. Srinivas, and A. V. Narsaiah, Tetrahedron Lett., 2007, 48,
7717; H. Galons, I. Bergerat, C. Combet Farnoux, and M. Miocque, Synthesis, 1982, 1103; M. P.

194
HETEROCYCLES, Vol. 81, No. 1, 2010
Groziak, S. R. Wilson, G. L. Clauson, and N. J. Leonard, J. Am. Chem. Soc., 1986, 108, 8002.
7. C. Enguehard, H. Allouchi, A. Gueiffier, and S. L. Buchwald, J. Org. Chem., 2003, 68, 4367; J.
Koubachi, S. E. Kazzouli, S. Berteina-Raboin, A. Mouaddib, and G. Guillaumet, J. Org. Chem.,
2007, 72, 7650; A. S. Kiselyov, Tetrahedron Lett., 2006, 47, 2941; R. Szabo, M. D. Crozet, and P.
Vanelle, Synthesis, 2008, 127.
8. Y. Q. Ge, J. Jia, Y. Li, L. Yin, and J. W. Wang, Heterocycles, 2009, 78, 197; Y. Q. Ge, J. Jia, H.
Yang, G. L. Zhao, F. X. Zhan, and J. W. Wang, Heterocycles, 2009, 78, 725.
9. K. L. Kirk, J. Org. Chem., 1978, 43, 4381; G. W. H. Cheeseman, J. Chem. Soc., 1964, 4645.
10. L. A. M. Bastiaansen and E. F. Godefroi, Synthesis, 1978, 675.
11. D. J. Hlasta, D. C. Bode, J. J. Court, R. C. Desai, E. D. Pagani, and P. J. Silver, Bioorg. Med. Chem.
Lett., 1997, 7, 89.